EXTON, Pa.--(BUSINESS WIRE)-- Melior Discovery, Inc. announced today that it has appointed Dr. John Gruner as Senior Scientific Fellow.
Dr. Gruner is a highly accomplished expert in evaluating the electrical properties of the nervous systems in living animals (in vivo neuro-electrophysiology). More particularly, Dr. Gruner is a leading authority in the study of the effects of drugs and drug candidates on the electrical activity of the brain and nerves. With over 35 years of experience, Dr. Gruner has made numerous significant contributions in the areas of sleep/wake behavior, spinal cord injury, and restoration of muscle function in paralyzed limbs. Dr. Gruner also has employed numerous motor neuron disease and in vivo pain models, and has developed a novel rodent method for the early detection of drug candidates that may cause seizures. Dr. Gruner has published extensively in a variety of disciplines and is the recipient of several scientific awards. Prior to joining Melior, Dr. Gruner was Senior Scientist at Cephalon for 18 years where his specialty towards evaluating drugs made key contributions to the approval of Nuvigil® and bringing other drugs to clinical trial stage. Dr. Gruner was also a member of the NASA Neurolab Space Shuttle program.
At Melior, Dr. Gruner will utilize his highly sophisticated expertise to augment Melior’s unique capabilities around high-throughput in vivo drug screening further enabling rapid screening of drug-candidates for their potential therapeutic benefit in a host of central nervous system disorders. These disease areas include neuropathic pain, sleep/wake activity, epilepsy, and neurodegenerative diseases amongst others.
“We are excited about the added capabilities that John brings to our team at Melior”, said Andrew Reaume PhD, CEO, Melior Discovery. The combination of John’s expertise with Melior’s already unique competence in high throughput in vivo pharmacology significantly extends the power of Melior’s theraTRACE® platform”
About Melior Discovery, Inc.
Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its unique theraTRACE® platform of multiplexed in vivo models. Melior is using this capability to build an internal pipeline of development candidates. Melior Discovery also partners with pharmaceutical and biopharmaceutical companies to expand their drug development pipelines by using the theraTRACE® platform, and individual animal models, in conjunction with the Company’s in-depth in vivo pharmacology expertise.
Melior Discovery is located in Exton, PA. The Company is privately held with investors that include Cammeby’s Capital Group, VenturEast, Osage Ventures, Mid-Atlantic Angel Group, and BioAdvance.
Andrew Reaume, Ph.D MBA, +1 610-280-0633 ext 239
President and CEO
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Pharmaceutical Diabetes